BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38061307)

  • 1. Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction.
    Tüchler A; De Pauw A; Ernst C; Anota A; Lakeman IMM; Dick J; van der Stoep N; van Asperen CJ; Maringa M; Herold N; Blümcke B; Remy R; Westerhoff A; Stommel-Jenner DJ; Frouin E; Richters L; Golmard L; Kütting N; Colas C; Wappenschmidt B; Rhiem K; Devilee P; Stoppa-Lyonnet D; Schmutzler RK; Hahnen E
    Breast; 2024 Feb; 73():103615. PubMed ID: 38061307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
    BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
    Gao C; Polley EC; Hart SN; Huang H; Hu C; Gnanaolivu R; Lilyquist J; Boddicker NJ; Na J; Ambrosone CB; Auer PL; Bernstein L; Burnside ES; Eliassen AH; Gaudet MM; Haiman C; Hunter DJ; Jacobs EJ; John EM; Lindström S; Ma H; Neuhausen SL; Newcomb PA; O'Brien KM; Olson JE; Ong IM; Patel AV; Palmer JR; Sandler DP; Tamimi R; Taylor JA; Teras LR; Trentham-Dietz A; Vachon CM; Weinberg CR; Yao S; Weitzel JN; Goldgar DE; Domchek SM; Nathanson KL; Couch FJ; Kraft P
    J Clin Oncol; 2021 Aug; 39(23):2564-2573. PubMed ID: 34101481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
    Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
    J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
    Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; ; ; Collonge-Rame MA; Cook J; Daly MB; Davidson R; de la Hoya M; de Putter R; Delnatte C; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Eeles R; Ejlertsen B; Engel C; Evans DG; Faivre L; Foretova L; Fostira F; Friedlander M; Friedman E; Frost D; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Giraud S; Glendon G; Godwin AK; Goldgar DE; González-Neira A; Greene MH; Gschwantler-Kaulich D; Hahnen E; Hamann U; Hanson H; Hentschel J; Hogervorst FBL; Hooning MJ; Horvath J; Hu C; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Izquierdo A; Jakubowska A; James PA; Janavicius R; John EM; Joseph V; Karlan BY; Kast K; Koudijs M; Kruse TA; Kwong A; Laitman Y; Lasset C; Lazaro C; Lester J; Lesueur F; Liljegren A; Loud JT; Lubiński J; Mai PL; Manoukian S; Mari V; Mebirouk N; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller A; Montagna M; Mouret-Fourme E; Mukherjee S; Mulligan AM; Nathanson KL; Neuhausen SL; Nevanlinna H; Niederacher D; Nielsen FC; Nikitina-Zake L; Noguès C; Olah E; Olopade OI; Ong KR; O'Shaughnessy-Kirwan A; Osorio A; Ott CE; Papi L; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Peterlongo P; Pfeiler G; Phillips KA; Prajzendanc K; Pujana MA; Radice P; Ramser J; Ramus SJ; Rantala J; Rennert G; Risch HA; Robson M; Rønlund K; Salani R; Schuster H; Senter L; Shah PD; Sharma P; Side LE; Singer CF; Slavin TP; Soucy P; Southey MC; Spurdle AB; Steinemann D; Steinsnyder Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Thull DL; Tischkowitz M; Tognazzo S; Toland AE; Trainer AH; Tung N; van Engelen K; van Rensburg EJ; Vega A; Vierstraete J; Wagner G; Walker L; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Yadav S; Yang X; Yannoukakos D; Zimbalatti D; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC;
    Genet Med; 2020 Oct; 22(10):1653-1666. PubMed ID: 32665703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
    Li H; Engel C; de la Hoya M; Peterlongo P; Yannoukakos D; Livraghi L; Radice P; Thomassen M; Hansen TVO; Gerdes AM; Nielsen HR; Caputo SM; Zambelli A; Borg A; Solano A; Thomas A; Parsons MT; Antoniou AC; Leslie G; Yang X; Chenevix-Trench G; Caldes T; Kwong A; Pedersen IS; Lautrup CK; John EM; Terry MB; Hopper JL; Southey MC; Andrulis IL; Tischkowitz M; Janavicius R; Boonen SE; Kroeldrup L; Varesco L; Hamann U; Vega A; Palmero EI; Garber J; Montagna M; Van Asperen CJ; Foretova L; Greene MH; Selkirk T; Moller P; Toland AE; Domchek SM; James PA; Thorne H; Eccles DM; Nielsen SM; Manoukian S; Pasini B; Caligo MA; Lazaro C; Kirk J; Wappenschmidt B; Spurdle AB; Couch FJ; Schmutzler R; Goldgar DE; ;
    Genet Med; 2022 Jan; 24(1):119-129. PubMed ID: 34906479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
    Lee A; Mavaddat N; Wilcox AN; Cunningham AP; Carver T; Hartley S; Babb de Villiers C; Izquierdo A; Simard J; Schmidt MK; Walter FM; Chatterjee N; Garcia-Closas M; Tischkowitz M; Pharoah P; Easton DF; Antoniou AC
    Genet Med; 2019 Aug; 21(8):1708-1718. PubMed ID: 30643217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
    Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Breast Cancer Risk Assessment for
    Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
    JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
    Teixeira N; van der Hout A; Oosterwijk JC; Vos JR; ; Devilee P; van Engelen K; Meijers-Heijboer H; van der Luijt RB; Kriege M; Mensenkamp AR; Rookus MA; van Roozendaal KE; Mourits MJE; de Bock GH
    Eur J Hum Genet; 2018 Jun; 26(6):848-857. PubMed ID: 29483665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
    van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
    Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.